 |
0 Diseases |  |
0 Trials |
|
0 Trials |  |
20 News |  |
- Prandimet (repaglinide/metformin) / Novo Nordisk
UNLOCKING TAILORED THERAPIES FOR MODY1 DIABETES USING GLUCOSE SENSORS: A SINGLE?PATIENT CASE REPORT () - Mar 6, 2024 - Abstract #ATTD2024ATTD_885;
While long?acting sulfonylureas remain the preferred therapy for MODY1, this case underscores the potential utility of sensor?derived glucose patterns as valuable tools in guiding tailored treatments. Such an approach offers the promise of preventing both hypoglycaemic events and the onset of microvascular complications, heralding a new era of precision medicine in the management of MODY1 diabetes.
- | Prandimet (repaglinide/metformin) / Novo Nordisk
Preclinical, Journal: In Vivo Evaluation of Nanoemulsion Formulations for Metformin and Repaglinide Alone and Combination. (Pubmed Central) - Jan 18, 2023
A statistically significant decrease was observed in the blood glucose values of the diabetic rats treated with nanoemulsion formulations containing active substance/substances, compared to diabetic rats (control) (p<0.05). Nanoemulsion formulations (especially nanoemulsion containing metformin HCl and repaglinide combination) have a better antidiabetic activity and are more effective in reducing oxidative stress caused by diabetes.
- Prandimet (repaglinide/metformin) / Novo Nordisk
Unexpected side effect in the elderly () - Oct 17, 2022 - Abstract #EUSEM2022EUSEM_1337;
Currently in treatment with paracetamol due to catarrhal symptoms...It is usually triggered by drugs, including mirtazapine. A highly suspect is mandatory due to its letality.
- Prandimet (repaglinide/metformin) / Novo Nordisk
Unexpected side effect in the elderly () - Oct 17, 2022 - Abstract #EUSEM2022EUSEM_1336;
Currently in treatment with paracetamol due to catarrhal symptoms...It is usually triggered by drugs, including mirtazapine. A highly suspect is mandatory due to its letality.
- Prandimet (repaglinide/metformin) / Novo Nordisk
Unexpected side effect in the elderly () - Oct 17, 2022 - Abstract #EUSEM2022EUSEM_1335;
Currently in treatment with paracetamol due to catarrhal symptoms...It is usually triggered by drugs, including mirtazapine. A highly suspect is mandatory due to its letality.
- Prandimet (repaglinide/metformin) / Novo Nordisk
Unexpected side effect in the elderly () - Oct 17, 2022 - Abstract #EUSEM2022EUSEM_1334;
Currently in treatment with paracetamol due to catarrhal symptoms...It is usually triggered by drugs, including mirtazapine. A highly suspect is mandatory due to its letality.
- Prandimet (repaglinide/metformin) / Novo Nordisk
IgG4-Related Autoimmune Pancreatitis Following RNA-Based COVID-19 Vaccination (Crown Ballroom) - Sep 4, 2022 - Abstract #ACG2022ACG_1926;
He was started on metformin and repaglinide but his blood sugar remained uncontrolled...He was started on prednisone 40mg daily with a tapering schedule...(B, C) Hypervascular arterial enhancing pancreatic head mass measuring up to 3.6 x 2.6 x 5.5 cm in the largest dimensions (D) Compared to prior studies (previous images), the pancreas is no longer swollen and edematous but appears somewhat atrophic. No definite enhancing masses seen in the head of the pancreas.
- | Prandimet (repaglinide/metformin) / Novo Nordisk
Journal: Principal Component Analysis and DoE-Based AQbD Approach to Multipurpose HPTLC Method for Synchronous Estimation of Multiple FDCs of Metformin HCl, Repaglinide, Glibenclamide and Pioglitazone HCl. (Pubmed Central) - Jul 8, 2022
The developed method can synchronously analyze multiple FDCs of MET which required several chromatographic methods. Hence, the present method is multipurpose-HPTLC for the synchronous estimation of multiple FDCs of MET which required minimum organic solvent, time and cost of analysis.
- || Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly, Prandimet (repaglinide/metformin) / Novo Nordisk
Clinical, Review, Journal: Long-term efficacy and safety of anti-hyperglycaemic agents in new-onset diabetes after transplant: Results from outpatient-based 1-year follow-up and a brief review of treatment options. (Pubmed Central) - Nov 7, 2021
Combination therapy was needed in most within 1-year. Linagliptin monotherapy was effective, without producing hypoglycaemia or weight gain.
- | Prandimet (repaglinide/metformin) / Novo Nordisk
Journal: Repaglinide and metformin loaded amberlite resin based floating microspheres for the effective management of type 2 diabetes. (Pubmed Central) - Oct 27, 2021
Linagliptin monotherapy was effective, without producing hypoglycaemia or weight gain. Floating microspheres containing drug resin complex were able to prolong drug release in an efficient way for a sustained period of time; as a result, profound therapeutic response was obtained.
- | Prandimet (repaglinide/metformin) / Novo Nordisk
Journal, Monotherapy: Comparison of Metformin and Repaglinide Monotherapy in the Treatment of New-Onset Type 2 Diabetes Mellitus. (Pubmed Central) - Mar 9, 2021
Conclusion Our study concluded that both metformin and repaglinide have similar anti-hyperglycemic effects. Repaglinide can be prescribed as an alternative drug to metformin in patients with new-onset diabetes mellitus.
- | Prandimet (repaglinide/metformin) / Novo Nordisk
New P4 trial: Dulaglutide in Diabetic Patients, Relationship Between Arterial Stiffness, Endothelial Function, Clinical and Laboratory Variables (clinicaltrials.gov) - Jan 31, 2019
P4, N=92, Completed, Sponsor: University of Palermo
- | Prandimet (repaglinide/metformin) / Novo Nordisk
Trial completion: A Pharmacokinetic Study to Compare Co-administration of Repaglinide and Metformin HCl to Administration of Combination Preparation of Those Two Components (clinicaltrials.gov) - May 13, 2013
P1, N=48, Completed, Sponsor: Dalim BioTech Co., Ltd.
Repaglinide can be prescribed as an alternative drug to metformin in patients with new-onset diabetes mellitus. Active, not recruiting --> Completed
- | Prandimet (repaglinide/metformin) / Novo Nordisk
New P1 trial: A Pharmacokinetic Study to Compare Co-administration of Repaglinide and Metformin HCl to Administration of Combination Preparation of Those Two Components (clinicaltrials.gov) - Jan 28, 2013
P1, N=48, Completed, Sponsor: Dalim BioTech Co., Ltd.
- ||| Prandimet (repaglinide/metformin) / Novo Nordisk
New P1 trial: Single Dose Pharmacokinetics of Repaglinide, Metformin and Combination Tablet in Fed Healthy Volunteers (clinicaltrials.gov) - Dec 7, 2011
P1, N=93, Completed, Sponsor: Novo Nordisk
- ||| Prandimet (repaglinide/metformin) / Novo Nordisk
New P1 trial: Single Dose Pharmacokinetics of Repaglinide, Metformin and Combination Tablet in Healthy Volunteers (clinicaltrials.gov) - Dec 7, 2011
P1, N=62, Completed, Sponsor: Novo Nordisk
- ||||| Prandimet (repaglinide/metformin) / Novo Nordisk
New P4 trial: Comparison of Metformin, Repaglinide or the Combination of Both in Subjects With Type 2 Diabetes (clinicaltrials.gov) - Oct 30, 2011
P4, N=182, Completed, Sponsor: Novo Nordisk